Bioray Laboratories
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Thalassemia, Beta
Assessments
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 45 participants |
| Official Title : | Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia |
| Actual Study Start Date : | 2024-12-08 |
| Estimated Primary Completion Date : | 2038-08-20 |
| Estimated Study Completion Date : | 2038-10-15 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 3 Years to 35 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510006
Not yet recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510006
Not yet recruiting
Shenzhen Children 's Hospital
Shenzhen, Guangdong, China, 510006
Not yet recruiting
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
Nanning, Guangxi, China, 530021
Not yet recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China, 510510
Not yet recruiting
Tianjin Institute of Hematology
Tianjin, Tianjin, China, 300000
Not yet recruiting
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
Guangxi, China, 530021